Bitcoin Surges As ETF Inflows Jump. Trump-Linked Miner Reports Results. | Investor's Business DailyTRENDING: [Rare Earth Stocks To Watch]----Cryptocurrency stocks are generally surging this week. powered by bitcoin's ETF-fueled rally to near $70,000 on Wednesday. Stablecoin issuer Circle and bitcoin miner Hut 8 diverged on their Wednesday results, which prompted a 32% spike for CRCL. Trump family-linked miner American Bitcoin rose on its Thursday-morning results. After the stock market close, MARA Holdings, ...

Robust financial performance driven by full year 2025 royalty revenue growth of 48% Reiterating 2026 financial guidance of $245-$285 million in revenues and adjusted earnings per diluted share1 of $8.00-$9.00 Conference call and webcast at 8:30 a.m. Eastern time today JUPITER, Fla., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and twelve months ended December 31, 2025, and provided an operating forecast and business updat ...

We came across a bullish thesis on Travere Therapeutics, Inc. on HalfBakedInnovations’s Substack by Biotech Distilled. In this article, we will summarize the bulls’ thesis on TVTX. Travere Therapeutics, Inc.'s share was trading at $30.07 as of February 9th. TVTX’s forward P/E was 26.32 respectively according to Yahoo Finance. 7 Best Dialysis and Kidney Disease Stocks to Buy yezry/Shutterstock.com Travere Therapeutics (TVTX) is a biotech company focused on rare kidney and metabolic diseases, with its lea ...

分组1 - Travere Therapeutics reported 4Q25 non-GAAP EPS of $0.37, aligning with expectations [1] - Revenue for the quarter was $129.6 million, representing a 73% year-over-year increase, but fell short of consensus by approximately $18 million [1]

Core Insights - Travere Therapeutics reported a revenue of $129.69 million for the quarter ended December 2025, reflecting a year-over-year increase of 73.4% [1] - The earnings per share (EPS) was $0.03, a significant improvement from -$0.73 in the same quarter last year, with an EPS surprise of +16.73% [1] - The reported revenue was below the Zacks Consensus Estimate of $142.46 million, resulting in a revenue surprise of -8.97% [1] Revenue Breakdown - Revenue from Tiopronin products / Thiola was $23.27 million, slightly above the estimated $21.9 million, but a decrease of 2.6% compared to the previous year [4] - Total net product sales reached $126.61 million, exceeding the average estimate of $125.35 million, marking a year-over-year increase of 72.2% [4] - Revenue from FILSPARI was $103.34 million, slightly above the estimated $103.05 million, representing a substantial increase of 108.2% year-over-year [4] - License and collaboration revenue was reported at $3.08 million, significantly lower than the average estimate of $15.33 million, but still showing a year-over-year increase of 148.3% [4] Stock Performance - Over the past month, shares of Travere have returned -1.4%, compared to a -0.8% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

分组1 - Travere Therapeutics reported quarterly earnings of $0.03 per share, aligning with the Zacks Consensus Estimate, compared to a loss of $0.73 per share a year ago, representing an earnings surprise of +16.73% [1] - The company posted revenues of $129.69 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 8.97%, and this is an increase from year-ago revenues of $74.79 million [2] - Travere has surpassed consensus EPS estimates four times over the last four quarters and topped consensus revenue estimates three times during the same period [2] 分组2 - The stock has underperformed, losing about 27.1% since the beginning of the year, while the S&P 500 has gained 0.5% [3] - The current consensus EPS estimate for the coming quarter is -$0.07 on $135 million in revenues, and for the current fiscal year, it is $0.62 on $673.01 million in revenues [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 36% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]

Travere Therapeutics (NasdaqGM:TVTX) Q4 2025 Earnings call February 19, 2026 04:30 PM ET Company ParticipantsBill Rote - Chief Research OfficerChris Cline - CFOEric Dube - President and CEOGavin Clark-Gartner - Managing Director of Biotechnology Equity ResearchJason Zemansky - Managing DirectorJula Inrig - Chief Medical OfficerNivi Nehra - VP of Corporate Communications and Investor RelationsPeter Heerma - Chief Commercial OfficerConference Call ParticipantsAlex Thompson - Managing Director and Senior Equit ...

Financial Data and Key Metrics Changes - For Q4 2025, the company reported U.S. net product sales of $126.6 million, with total net product sales for the full year reaching $410.5 million, marking significant year-over-year growth [24][29] - FILSPARI generated approximately $103 million in net product sales for Q4 2025, resulting in $322 million for the full year, representing a 144% year-over-year growth [19][24] - The company achieved a net income of $2.7 million for Q4 2025, compared to a net loss of $60.3 million for the same period in 2024 [29] Business Line Data and Key Metrics Changes - FILSPARI saw record demand with 908 new patient starts in Q4 2025, driven by strong physician adoption and confidence in its role as a foundational therapy in IgA nephropathy [18][19] - Thiola and Thiola EC contributed $23.3 million in U.S. net product sales during Q4 2025, totaling $88.5 million for the full year [25] Market Data and Key Metrics Changes - The company noted that over 96% of the patient population has a pathway to reimbursement for FILSPARI, indicating strong payer support despite new competition [37] - There is increasing adoption of FILSPARI among patients with proteinuria levels below 1.5 grams per gram, which represents approximately two-thirds of the addressable IgA nephropathy population [21] Company Strategy and Development Direction - The company aims to solidify FILSPARI's foundational role in IgA nephropathy, successfully deliver the first approved medicine for FSGS, and advance enrollment in the Phase 3 HARMONY Study [9][30] - The strategy includes expanding the commercial team and preparing for a potential launch in FSGS, which is expected to be a larger opportunity compared to IgA nephropathy [22][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued growth of FILSPARI in IgA nephropathy and the potential for FSGS, emphasizing the urgency to deliver meaningful progress for patients [5][32] - The company anticipates meaningful net product sales growth from FILSPARI and IgA nephropathy, with a focus on thoughtful investments to support long-term growth [30][31] Other Important Information - The company received a major amendment notification for its sNDA for FSGS, with a new FDA PDUFA target action date set for April 13, 2026 [7][8] - Pegtibatinase for classical homocystinuria is also advancing, with resumed site activation for the pivotal Phase 3 HARMONY study [8][16] Q&A Session Summary Question: Can you provide more detail on IgA performance and the prescribing landscape? - Management noted strong demand driven by REMS modifications and KDIGO publication, with the majority of utilization occurring in community settings [35][37] Question: Have there been significant data requests from the FDA regarding FSGS? - Management confirmed ongoing engagement with the FDA and expressed confidence in the data supporting FILSPARI's potential treatment for FSGS [46][68] Question: What is the sales infrastructure for IgAN and how will it expand for FSGS? - The prescriber base for FSGS is similar to IgA nephropathy, with an expanded field team already operational to optimize opportunities [57][60] Question: How do you view FILSPARI's market penetration and growth potential? - Management indicated that FILSPARI has not yet penetrated 10% of the addressable patient population, suggesting significant growth opportunities ahead [77][80]

Travere Therapeutics (NasdaqGM:TVTX) Q4 2025 Earnings call February 19, 2026 04:30 PM ET Speaker3Good afternoon, and welcome to the Travere Therapeutics fourth quarter and full year 2025 financial results conference call. Today's call is being recorded. At this time, I would like to turn the conference call over to Nivi Nehra, Vice President, Corporate Communications and Investor Relations. Please go ahead, Nivi.Speaker4Thank you, operator. Good afternoon, and welcome to Travere Therapeutics' fourth quarter ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...